Press release
Chondrosarcoma Pipeline Analysis, 2024 | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest Approvals, Key Companies, Treatment Algorithm
Chondrosarcoma Pipeline Insights 2024
As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Chondrosarcoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Key highlights of the Chondrosarcoma pipeline insights report:
*
Novel therapies targeting IDH mutations have the potential to make a significant impact in the chondrosarcoma treatment landscape, capturing a substantial share of the untapped market, given that nearly 65% of chondrosarcoma cases are linked to IDH mutations.
*
According to the updated NCCN guidelines, ivosidenib has now been included as a treatment option for patients with IDH1-mutant conventional or dedifferentiated chondrosarcoma.
*
Additionally, the ESMO 2021 clinical practice guidelines for diagnosis, treatment, and follow-up suggest that trabectedin could be considered as a treatment option for mesenchymal chondrosarcoma.
*
INBRX-109, one of the leading candidates in the emerging treatment landscape, shows promise as a new therapeutic option for patients with unresectable conventional chondrosarcoma, offering the potential to extend progression-free survival (PFS) while demonstrating an improved safety profile.
"Chondrosarcoma Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chondrosarcoma Market.
The Chondrosarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Chondrosarcoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the emerging therapies for the treatment of Chondrosarcoma and the aggregate therapies developed by major pharma companies.
*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chondrosarcoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Route of Administration
Chondrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
*
Molecule Type
Products have been categorized under various Molecule types such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Learn How the Ongoing Clinical & Commercial Activities will Affect the Chondrosarcoma Therapeutic Segment @ https://www.delveinsight.com/report-store/chondrosarcoma-pipeline-insight [https://www.delveinsight.com/report-store/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Chondrosarcoma Therapeutics Landscape [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Several major pharma and biotech companies are developing therapies for Chondrosarcoma. Currently, Inhibrx is leading the therapeutics market with its Chondrosarcoma drug candidates in the most advanced stage of clinical development.
Emerging Chondrosarcoma Drugs
INBRX-109: Inhibrx
INBRX-109, Inhibrx's most advanced therapeutic candidate, is designed to induce tumor-specific cell death by activating the DR5 receptor, which is involved in the apoptosis of cancer cells. DR5 is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its activation selectively eliminates damaged or neoplastic cells, while normal cells are generally more resistant to DR5-mediated cell death.
INBRX-109 is a tetravalent DR5 agonistic antibody that enhances DR5 signaling through efficient receptor clustering, leading to targeted cancer cell death. The drug is currently being tested in a Phase II trial with the potential to support regulatory approval. Inhibrx expects topline results from this pivotal trial in the second half of 2024, which could pave the way for INBRX-109's approval for chondrosarcoma by 2025.
TIBSOVO (ivosidenib): Servier
TIBSOVO, developed by Servier, is an isocitrate dehydrogenase-1 (IDH1) inhibitor. A Phase III, multicenter, double-blind, randomized, placebo-controlled trial is currently underway to evaluate ivosidenib in patients aged 18 and older with locally advanced or metastatic conventional chondrosarcoma harboring an IDH1 mutation. This study includes both treatment-naive patients and those previously treated with a single systemic regimen, and is expected to be completed by 2031.
Key Companies in the Chondrosarcoma Therapeutic Market Include:
*
Inhibrx, Inc.
*
PharmaMar
*
Agios Pharmaceuticals
*
Iovance Biotherapeutics
*
Forma Therapeutics
*
Eli Lilly and Company
*
IGM Biosciences, Inc.
*
AnHeart Therapeutics
*
Roche
*
Salarius Pharmaceuticals
*
And Many Others
Chondrosarcoma Therapies Covered in the Report Include:
*
INBRX-109: Inhibrx
*
AG120: Agios Pharmaceuticals
*
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Chondrosarcoma Current Treatment Patterns
4. Chondrosarcoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chondrosarcoma Late Stage Products (Phase-III)
7. Chondrosarcoma Mid-Stage Products (Phase-II)
8. Chondrosarcoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chondrosarcoma Discontinued Products
13. Chondrosarcoma Product Profiles
14. Key Companies in the Chondrosarcoma Market
15. Key Products in the Chondrosarcoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Chondrosarcoma Unmet Needs
18. Chondrosarcoma Future Perspectives
19. Chondrosarcoma Analyst Review
20. Appendix
21. Report Methodology
Download Sample PDF to Explore the Key Offerings of the Report: https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chondrosarcoma-pipeline-analysis-2024-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-approvals-key-companies-treatment-algorithm]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chondrosarcoma Pipeline Analysis, 2024 | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest Approvals, Key Companies, Treatment Algorithm here
News-ID: 3749910 • Views: …
More Releases from ABNewswire
How Local Movers Are Shaping Nashville's Neighborhood Growth: Insights from 6th …
6th Man Movers examines how Nashville's moving industry supports neighborhood growth, new resident integration, and commercial development across Middle Tennessee's expanding communities.
Nashville continues to experience rapid population growth, with new residents arriving daily from across the country. This influx has created a ripple effect throughout Middle Tennessee's housing market, local economy, and infrastructure. At the center of this transformation sits the moving industry, which plays a significant yet often overlooked…
On Call Moving Company Addresses Growing Need for Professional Packing Services …
On Call Moving Company expands professional packing services in Oklahoma City and Tulsa, offering residential and commercial clients expert solutions, quality materials, and flexible options for stress-free relocations.
A moving company [https://maps.app.goo.gl/iTSxMWbAAKt5abDj6#moving+company] that understands the complexities of relocation can make all the difference during major life transitions. The relocation industry continues to evolve as households and businesses seek ways to reduce the time and stress associated with moving. On Call Moving…
Preferred Medical Group Strengthens Family Practice Auburn Families Trust with E …
Preferred Medical Group expands comprehensive healthcare in Auburn, offering integrated services from pediatrics to behavioral health, including ADHD care, therapy services, and same-day urgent care for families.
Healthcare access continues to evolve in Auburn, Alabama, as Preferred Medical Group [http://finance.minyanville.com/minyanville/article/abnewswire-2025-11-5-how-to-see-a-psychiatrist-immediately-auburn-medical-centers-launch-rapid-mental-health-access-programs-for-adhd-doctor-consultations] strengthens its commitment to serving families across the region. The medical practice has expanded its comprehensive services to meet growing demand for quality healthcare, offering everything from pediatric care to behavioral…
Preferred Medical Group Expands Integrated Care Model for Pediatrics Opelika Fam …
Preferred Medical Group in Opelika provides integrated healthcare combining pediatric and adult medicine, behavioral health services, ADHD evaluation, and specialized therapies for children at one accessible location.
Pediatric opelika services [https://maps.app.goo.gl/C9nc5Cpinahhr2Gx8#pediatrics+opelika] have evolved to meet the complex healthcare needs of modern families. Preferred Medical Group has established a comprehensive care framework that addresses multiple aspects of family health under one roof. The Opelika-based practice combines traditional medical services with specialized therapeutic…
More Releases for Chondrosarcoma
Chondrosarcoma Pipeline: Advancing Therapeutics and 15+ Leading Companies Shapin …
The therapeutic landscape for Chondrosarcoma, a rare and aggressive bone cancer, is rapidly evolving, driven by advances in molecular biology, targeted therapies, and a deeper understanding of the tumor's genetic and cellular mechanisms. Leading biopharmaceutical companies like PharmaMar and Salarius Pharmaceuticals are at the forefront, focusing on innovative approaches to target key pathways such as cartilage-specific mutations, tumor microenvironment modulation, and immune checkpoint inhibition for the treatment of Chondrosarcoma.
DelveInsight's "Chondrosarcoma…
Chondrosarcoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse C …
DelveInsight's, "Chondrosarcoma Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Chondrosarcoma pipeline landscape. It covers the Chondrosarcoma pipeline drug profiles, including Chondrosarcoma clinical trials and nonclinical stage products. It also covers the Chondrosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Chondrosarcoma emerging drugs, the Chondrosarcoma…
Chondrosarcoma Treatment Market Rugged Expansion Foreseen by 2022
Chondrosarcoma refers to cancer of cartilage, a flexible connective tissue found in joints between bones, the ear, the rib cage etc. According to Cancer Network Journal, chondrosarcoma contributes to almost half of the osteosarcoma cases and is the second most common type of osteosacrcoma (tumor of bones). Chondrosarcoma can start at any age but most commonly found in adults above the age of 20 years. As per the statistics of…
Chondrosarcoma - Pipeline Review, H1 2017 - Pharmaceutical Market Report
Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.
Request Free Sample…
Chondrosarcoma Treatment Market is Growing at Significant Rate by 2022
Chondrosarcoma refers to cancer of cartilage, a flexible connective tissue found in joints between bones, the ear, the rib cage etc. According to Cancer Network Journal, chondrosarcoma contributes to almost half of the osteosarcoma cases and is the second most common type of osteosacrcoma (tumor of bones). Chondrosarcoma can start at any age but most commonly found in adults above the age of 20 years. As per the statistics of…
Future of Global Chondrosarcoma Treatment Market : 2016 - 2022
Chondrosarcoma refers to cancer of cartilage, a flexible connective tissue found in joints between bones, the ear, the rib cage etc. According to Cancer Network Journal, chondrosarcoma contributes to almost half of the osteosarcoma cases and is the second most common type of osteosacrcoma (tumor of bones). Chondrosarcoma can start at any age but most commonly found in adults above the age of 20 years. As per the statistics of…
